PE20251551A1 - Compuestos de pirazolopirimidina y su uso medico - Google Patents
Compuestos de pirazolopirimidina y su uso medicoInfo
- Publication number
- PE20251551A1 PE20251551A1 PE2025000467A PE2025000467A PE20251551A1 PE 20251551 A1 PE20251551 A1 PE 20251551A1 PE 2025000467 A PE2025000467 A PE 2025000467A PE 2025000467 A PE2025000467 A PE 2025000467A PE 20251551 A1 PE20251551 A1 PE 20251551A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- adjacent
- carbon
- nitrogen
- oxygen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a compuestos de pirazolopirimidina con actividad inhibidora de inflamasoma NLRP3, de formula (IA) o una de sus sales farmaceuticamente aceptables, en el cual las lineas discontinuas representan a un enlace simple o doble; R1, R2 y R5A son cada uno, de modo independiente, hidrogeno, ciano, entre otros; R3A y R4A son cada uno, de modo independiente, hidrogeno, alquilo de C1-4 o haloalquilo de C1-4; R6A es, de modo independiente, alcoxi de C1-4, halogeno, entre otros; m es 0, 1 o 2, siempre que, cuando m es 2, luego dos R6A adyacentes se puedan combinar junto con los dos atomos adyacentes entre X1, X2, X3, X4y X5a los que se unen para formar heterocicloalcano de 5 a 7 miembros o heterocicloalqueno que comprende 1 o 2 heteroatomos seleccionados, de modo independiente, del grupo que consiste en atomo de nitrogeno y oxigeno; n es 0 o 1, siempre que, cuando n es 0, luego X1, X2, X3y X4 sean cada uno, de modo independiente, atomo de carbono, nitrogeno, oxigeno o azufre, en donde una cantidad total de atomos de nitrogeno, oxigeno y azufre como X1, X2, X3 o X4 es 1, 2 o 3 y una cantidad total de atomos de oxigeno y azufre es 0 o 1 y X1, X2, X3 y X4 se combinan junto con el atomo de carbono que es adyacente a X1 y X4 para formar heteroarilo, y siempre que, cuando n es 1, luego X1, X2, X3, X4 y X5 sean cada uno, de modo independiente, atomo de carbono o nitrogeno, en donde una cantidad total de atomos de nitrogeno como X1, X2, X3, X4 o X5 es 1 o 2 y X1, X2, X3, X4 y X5 se combinan junto con el atomo de carbono que es adyacente a X1 y X5 para formar heteroarilo. Tambien se refiere a una composicion farmaceutica que contiene el compuesto o una de sus sales farmaceuticamente aceptables, junto con un portador farmaceuticamente aceptable; al medicamento que lo contiene, al compuesto o sus sales en si mismos, y a la administracion de una cantidad terapeuticamente eficaz de estos para tratar o prevenir una enfermedad, como la esclerosis multiple, una enfermedad intestinal inflamatoria, entre otras.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022135949 | 2022-08-29 | ||
| JP2023027426 | 2023-02-24 | ||
| PCT/JP2023/030980 WO2024048519A1 (ja) | 2022-08-29 | 2023-08-28 | ピラゾロピリミジン化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20251551A1 true PE20251551A1 (es) | 2025-06-05 |
Family
ID=90099947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025000467A PE20251551A1 (es) | 2022-08-29 | 2023-08-28 | Compuestos de pirazolopirimidina y su uso medico |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250114361A1 (es) |
| EP (1) | EP4582428A1 (es) |
| JP (2) | JP7585409B2 (es) |
| KR (1) | KR20250056233A (es) |
| CN (1) | CN119790055A (es) |
| AR (1) | AR130318A1 (es) |
| AU (1) | AU2023334673A1 (es) |
| CL (1) | CL2025000495A1 (es) |
| CO (1) | CO2025002359A2 (es) |
| IL (1) | IL319000A (es) |
| MX (1) | MX2025002450A (es) |
| PE (1) | PE20251551A1 (es) |
| TW (1) | TW202416965A (es) |
| WO (1) | WO2024048519A1 (es) |
| ZA (1) | ZA202501724B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120752239A (zh) * | 2023-02-24 | 2025-10-03 | 日本烟草产业株式会社 | 经取代的吡唑并嘧啶化合物及其医药用途 |
| CN120731207A (zh) * | 2023-02-24 | 2025-09-30 | 日本烟草产业株式会社 | 6-烷氧基吡唑并嘧啶化合物及其药学用途 |
| TW202506678A (zh) | 2023-04-14 | 2025-02-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| WO2025140708A1 (zh) * | 2023-12-31 | 2025-07-03 | 杭州百新生物医药科技有限公司 | 吡唑并嘧啶类化合物及其医药用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4146348T3 (da) * | 2020-05-08 | 2024-09-30 | Halia Therapeutics Inc | Inhibitorer af nek7-kinase |
| AU2021346847A1 (en) * | 2020-09-24 | 2023-06-08 | Janssen Pharmaceutica Nv | New compounds |
| CN113549080B (zh) * | 2021-08-27 | 2023-05-16 | 中国医学科学院放射医学研究所 | 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途 |
| AU2022340126A1 (en) * | 2021-08-31 | 2024-04-11 | Japan Tobacco Inc. | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof |
-
2023
- 2023-08-28 AU AU2023334673A patent/AU2023334673A1/en active Pending
- 2023-08-28 EP EP23860281.7A patent/EP4582428A1/en active Pending
- 2023-08-28 TW TW112132370A patent/TW202416965A/zh unknown
- 2023-08-28 IL IL319000A patent/IL319000A/en unknown
- 2023-08-28 KR KR1020257009740A patent/KR20250056233A/ko active Pending
- 2023-08-28 AR ARP230102274A patent/AR130318A1/es unknown
- 2023-08-28 JP JP2023137929A patent/JP7585409B2/ja active Active
- 2023-08-28 CN CN202380062735.4A patent/CN119790055A/zh active Pending
- 2023-08-28 PE PE2025000467A patent/PE20251551A1/es unknown
- 2023-08-28 WO PCT/JP2023/030980 patent/WO2024048519A1/ja not_active Ceased
- 2023-08-28 US US18/705,065 patent/US20250114361A1/en active Pending
-
2024
- 2024-11-06 JP JP2024194113A patent/JP2025013515A/ja active Pending
-
2025
- 2025-02-21 CL CL2025000495A patent/CL2025000495A1/es unknown
- 2025-02-25 ZA ZA2025/01724A patent/ZA202501724B/en unknown
- 2025-02-27 MX MX2025002450A patent/MX2025002450A/es unknown
- 2025-02-27 CO CONC2025/0002359A patent/CO2025002359A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202501724B (en) | 2025-11-26 |
| WO2024048519A1 (ja) | 2024-03-07 |
| MX2025002450A (es) | 2025-04-02 |
| TW202416965A (zh) | 2024-05-01 |
| KR20250056233A (ko) | 2025-04-25 |
| CL2025000495A1 (es) | 2025-06-13 |
| IL319000A (en) | 2025-04-01 |
| JP7585409B2 (ja) | 2024-11-18 |
| AU2023334673A1 (en) | 2025-03-27 |
| EP4582428A1 (en) | 2025-07-09 |
| CO2025002359A2 (es) | 2025-03-27 |
| JP2024032686A (ja) | 2024-03-12 |
| US20250114361A1 (en) | 2025-04-10 |
| AR130318A1 (es) | 2024-11-27 |
| JP2025013515A (ja) | 2025-01-24 |
| CN119790055A (zh) | 2025-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20251551A1 (es) | Compuestos de pirazolopirimidina y su uso medico | |
| ES2690341T3 (es) | Derivados de 2-amino-5-trifluorometil-pirimidina y su uso como inhibidores de la quinasa PTK2 | |
| IL278297B2 (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| PE20240882A1 (es) | Compuestos de 6-aminopirazolopirimidina y su uso medico | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| CO2018005854A2 (es) | Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos | |
| RU2007116858A (ru) | Тиазолилдигидроиндазолы | |
| IL302896A (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| AR132802A1 (es) | 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer | |
| CA2422367A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| EA200000700A2 (ru) | НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| RU2012109554A (ru) | Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией | |
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| RU2014120421A (ru) | Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| JP2014530837A5 (es) | ||
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| AR120174A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| RU2389719C3 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| AR071049A1 (es) | Uso de n- fenilamidas de acido 2- sulfonilaminobenzoidco sustituidas con sulfonilo en el tratamiento del dolor |